Abstract
Antiviral vaccines classically were composed of attenuated or inactivated whole virions produced by infection of eukaryotic cells. With the advent of recombinant DNA (rDNA) technology, the strategy for vaccine production has changed dramatically. The gene(s) encoding a specific protein(s) containing the virus neutralizing site(s) can be isolated and transfected into bacteria, yeast or mammalian cells in culture. These transfected or recombinant organisms or cells can be exploited to produce large quantities of the specific protein which subsequently can be developed in a highly purified form for use as a subunit vaccine. The issue which we would like to discuss is the selection of the host used for the expression of recombinant subunit vaccines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
